An open randomized prospective clinical study to evaluate comparative efficacy of DRF/AY/5023 with Bournvita in overallgrowth of children attending primary school

Dabur India Limited0 个研究点目标入组 160 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male & female children with age not more than 12 years.
•2. Medically stable with no requirement of drugs,or any interventions/procedures or any neutraceutical / health supplement.
•3. Permission was obtained from the parents of all children and willing to sign an informed consent.
•4. Parents and teacher of the child willing to sign an informed consent

•1. Children with any underlying physical or mental illness.
•2. Children who required use of concomitant medications known to adversely interact with study drug.
•3. Known Hypersensitivity to study drug or ingredients in the study drug
•4. Required use of concomitant medication known to adversely interact with study drug
•5. Subjects participating in other clinical trials
•6. Parents and teachers of the children not willing to sign Informed Consent

发起方